The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics
- 23 November 2011
- journal article
- Published by Springer Nature in Apoptosis
- Vol. 17 (2) , 164-173
Abstract
1α,25-Dihydroxyvitamin D3, (1,25-D3) the biologically active form of vitamin-D, is well established as a cancer cell growth inhibitor in addition to maintaining bone mineralization. In breast cancer cells, inhibitory effects on angiogenesis, and metastasis have been observed together with enhancement of apoptosis and induction of cell cycle arrest. There is a correlation between vitamin-D receptor expression on breast cancer cells and patient survival. However vitamin-D resistance and hypercalcaemia are key limiting factors in clinical use. The IMiD® immunomodulatory drug lenalidomide, (Revlimid®, CC-5013) used in myeloma, can also modulate apoptotic and growth signalling. We studied whether lenalidomide treated breast cancer cells would acquire sensitivity to 1,25-D3 with resulting growth inhibition. The cell lines MCF-12A, MCF-7 and MDA-MB-231, representing non-tumorogenic, tumorogenic, and vitamin-D resistant lines respectively were treated with lenalidomide and/or 1,25-D3(at 100 nM). Whereas lenalidomide alone had no effect on cell growth, a 50% inhibition of cell growth by 1,25-D3 was achieved with additional 1 μM lenalidomide in resistant cells. This effect was through apoptosis measured by PARP cleavage and annexin-V expression. An apoptosis protein array showed that the 1,25-D3 and lenalidomide combination increased pro-apoptotic proteins (phosphorylated p53) and decreased BCL-2 expression. BCL-2 inhibition is proposed as a mechanism of action for the combined drugs in the MDA-MB-231 cell line. In vitamin D resistant cell lines MCF-7VDR and HBL-100 where the combination does not affect BCL-2—no inhibitory effect is observed. These results demonstrate the potential for the combinatorial use of lenalidomide and 1,25-D3 for vitamin D refractory tumours.Keywords
This publication has 30 references indexed in Scilit:
- Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)British Journal of Cancer, 2009
- Lenalidomide: a novel anticancer drug with multiple modalitiesExpert Opinion on Pharmacotherapy, 2008
- Bcl-2 inhibitors: small molecules with a big impact on cancer therapyCell Death & Differentiation, 2008
- Mammary epithelial cell transformation is associated with deregulation of the vitamin D pathwayJournal of Cellular Biochemistry, 2008
- Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft ModelsClinical Cancer Research, 2008
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family InhibitorCancer Research, 2008
- Identification of novel mediators of Vitamin D signaling and 1,25(OH)2D3 resistance in mammary cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer.Endocrine-Related Cancer, 2002
- MCF‐7/VDR: A new vitamin D resistant cell lineJournal of Cellular Biochemistry, 2001
- Mammary gland 1, 25-dihydroxyvitamin D3 receptor content during pregnancy and lactationMolecular and Cellular Endocrinology, 1988